首頁 > 市場調查報告書 > 製藥

生物製劑分子標靶治療學

抗體藥物偶聯物 (ADC) 市場 - 按癌症類型、有效載荷、標靶、產品、用戶和國家劃分的市場預測（含高階主管和顧問指南）：2026-2030

市場調查報告書

商品編碼

1898725

抗體藥物偶聯物 (ADC) 市場 - 按癌症類型、有效載荷、標靶、產品、用戶和國家劃分的市場預測（含高階主管和顧問指南）：2026-2030

Antibody Drug Conjugates Markets. ADC Market Forecasts by cancer, by payload, by target, by product, by user and by country/region including Executive and Consultant Guides. 2026 to 2030

出版日期: 2025年12月28日 | 出版商:

Howe Sound Research | 英文 388 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄圖表

報告概述：

透過我們最新的報告了解該市場。我們分析了 100 家尋求發展機會的公司，並闡述了它們的計劃。詳細的市場分析僅用幾頁篇幅就展現了完整的市場概況。

從各個角度分析市場：癌症類型、酬載、標靶、產品、使用者和國家。了解市場機會。

該市場已是一個數十億美元的全球市場，並蓄勢待發，即將迎來爆發式增長。它對醫療保健行業的影響巨大。本報告預測了未來五年的市場規模。

識別機會和挑戰，了解成長預測和最終市場規模潛力。

所有報表資料可依需求提供 Excel 格式。

利用最新數據和全面分析，做出自信的決策。

成長驅動因素
- 潛在結果
- 快速通道
- 資金
- 科技環境
- 標靶解決方案
成長限制因素
- 治療成本
- 臨床試驗的作用
- 合併用藥
- 方案
治療技術開發
- 合併用藥－問題與複雜性
- 藥物偏好
- 免疫工程挑戰
- 成本的作用
- 顛覆性動態
2024年全球抗體藥物偶聯物 (ADC) 銷售額

第六章近期ADC最新進展

最新進展 - 本部分的重要性和用途
默克獲得7億美元用於ADC療法的開發
Enhertu超越羅氏的Kadsila
信達生物與武田簽署114億美元的癌症治療協議
Tubuli融資3.58億美元用於開發標靶癌症療法
羅氏簽署8000萬美元的肺癌ADC協議
Trodelvy和Keytruda聯合療法在3期臨床試驗中取得成功
葛蘭素史克獲得前列腺癌ADC的權利
三星Bioepis和Phrontline合作開發ADC
Phrontline Biopharma融資6000萬美元用於雙特異性和雙有效載荷ADC
Kelun的ADC-Keytruda突破3期臨床試驗組合
達托泊單抗（Datopotamab Deruxtecan）生物製劑許可申請核准
FDA核准第一三共和阿斯特捷利康的實體腫瘤治療藥物
阿斯特捷利康將投資15億美元興建ADC工廠
三星生物製劑拓展ADC生產與服務業務
益普生和Foreseen Biotechnology宣布ADC許可協議
PDC與ADC：開拓新領域
MilliporeSigma推出用於ADC生產的一次性反應器
小野洋子研發出新型ADC候選藥物
吉利德和Tubulis開發用於實體腫瘤的ADC候選藥物

第七章：主要ADC公司概覽

ADC療法
艾伯維
阿布澤納
Adcendo
Adcentrx 療法
Adcytherix
Alentis 療法
康寧傑瑞腫瘤學
Alteogen
Ambrx
安進
Antengene
安斯泰來製藥
Axcynsis 療法
Axplora
百濟神州
BeOne 藥品
生物阿特拉
百奧泰解決方案
比奧修斯
BiVictriX 療法
生物科技
自行車治療
博爾特生物療法
明峰療法
百時美施貴寶(BMS)
Byondis
Callio Therapeutics
Catalent Biologics
CSPC Pharmaceutical Group
CytomX Therapeutics
Daiichi Sankyo
Debiopharm
Duality Biologics
Eisai
Eli Lilly
Exelixis
Fosun Pharma
Genentech (Roche)
Genmab
GenScript Biotech
Gilead Sciences
GlaxoSmithKline (GSK)
Hansoh Pharma
Hengrui Pharma
Heidelberg Pharma
Iksuda Therapeutics
ImmunoGen
Innate Pharma
Innovent Biologics
iProgen生物技術
楊森生物技術（強生公司）
科倫生物技術
KLUS製藥
樂高化學生物科技（樂高化學生物）
樂普生物製藥
龍沙製藥/Synaffix
MacroGenics
MBrace Therapeutics
MediLink Therapeutics
默克公司（默沙東）
默克集團（EMD Serono）
Mersana Therapeutics
Molecular Templates
NBE Therapeutics（勃林格殷格翰子公司）
諾華
OBI Pharma
OmniAb
Oncomatryx
OnCusp Therapeutics
Orum治療藥物
Oqory
Oxford BioTherapeutics
Pacylex Pharmaceuticals
輝瑞
Phrontline Biopharma
ProfoundBio
Promega
Pyxis Oncology
Radiance Biopharma
Rakuten Aspyrian (Aspyrian Therapeutics)
RemeGen
羅氏
榮昌製藥 (RCBio)
賽諾菲
Seagen
Solve Therapeutics (Solve Tx)
Sorrento Therapeutics
Starpharma
Sutro Biopharma
Synaffix (Lonza旗下公司)
SystImmune
武田製藥
Tesaro/葛蘭素史克腫瘤學
Tubulis
UCB
VelosBio
藥明康德
Xencor
再鼎醫藥

第八章：全球抗體偶聯藥物（ADC）市場

全球市場概覽（依國家/地區劃分）
全球市場概覽（依癌症類型劃分）
全球市場概覽（依有效載荷劃分）
全球市場概覽（以標靶劃分）
全球市場概覽（依產品劃分）
全球市場概覽（依使用者劃分）

第九章：全球ADC市場（依癌症類型劃分）

乳癌
血液和淋巴系統癌症
肺癌
其他

第十章：ADC市場有效負載

阿里他汀類藥物
美登木素生物鹼
拓樸異構酶
其他

第 11 章 ADC 治療市場 - 按目標

HER2
CD30
TROP2
CD79b
Nectin-4
其他

第 12 章 ADC 治療市場 - 按產品

恩赫圖
卡德西拉
帕德切夫
Adcetris
特羅德夫
Polyvy
其他

第 13 章 ADC 治療市場 - 作者使用者

臨床
試用
研究
其他

第 14 章：附錄

簡介目錄圖表

Report Overview:

Get a handle on this market with our latest report. We analyze 100 Companies who are rushing after the opportunity and explain their plans. A detailed Situation Analysis sums up the big picture in a few pages.

We look at the market from every angle: Cancer, Payload, Target, Product, User and Country. Understand this market opportunity.

Already worth billions the global market is poised for dramatic growth. The impact on the health care industry is enormous. The report forecasts the market size out for five years.

Find the opportunities and the pitfalls. Understand growth expectations and the ultimate potential market size.

All report data is available in Excel format on request.

Make decisions with confidence using the latest data and comprehensive analysis.

1 Market Guides

1.1 Situation Analysis
1.2 Guide for Executives and Marketing Staff
1.3 Guide for Investment Analysts and Management Consultants

2 Introduction and Market Definition

2.1 What are Antibody Drug Conjugates?
2.2 Immunotherapy - the looming cures
2.3 Market Definition
- 2.3.1 Market Size
- 2.3.2 Currency
- 2.3.3 Years
2.4 Methodology
- 2.4.1 Methodology
- 2.4.2 Sources
- 2.4.3 Authors
2.5 U.S. Medical Market and Pharmaceutical Spending - Perspective
- 2.5.1 Global Expenditures for Medicines

3 Antibody Drug Conjugates

3.1 The Immune System
- 3.1.1 Innate immune system
  - 3.1.1.1 Surface barriers
  - 3.1.1.2 Inflammation
  - 3.1.1.3 Complement system
  - 3.1.1.4 Cellular barriers
  - 3.1.1.5 Natural killer cells
- 3.1.2 Adaptive immune system
  - 3.1.2.1 Lymphocytes
  - 3.1.2.2 Killer T cells
  - 3.1.2.3 Helper T cells
  - 3.1.2.4 Gamma delta T cells
  - 3.1.2.5 B lymphocytes and antibodies
- 3.1.3 Tumor immunology - the immune surveillance system
3.2 ADC Technology
- 3.2.1.1 Outlook for Antibody Drug Conjugates
- 3.2.1.2 Selected Companies with Antibody Drug Conjugates in their Pipeline

4 Industry Overview

4.1 Market Players - Roles & Impacts
- 4.1.1 Drug manufacturers - Larger/pharmaceutical
- 4.1.2 Drug manufacturers - Generic
- 4.1.3 Contract Research and Manufacturing
- 4.1.4 In Vitro Diagnostics Industry
- 4.1.5 Drug Marketing Companies
- 4.1.6 Biotechnology Companies
- 4.1.7 Regulatory Bodies

5 Market Trends

5.1 Factors Driving Growth
- 5.1.1 Outcome potential
- 5.1.2 Fast tracking
- 5.1.3 Funding
- 5.1.4 Technology Environment
- 5.1.5 Target Solutions
5.2 Factors Limiting Growth
- 5.2.1 Cost of Treatment
- 5.2.2 Clinical Trials Role
- 5.2.3 Combinations
- 5.2.4 Protocols
5.3 Therapeutic Technology Development
- 5.3.1 Combinations - Issues and Complexity
- 5.3.2 Preference for a drug
- 5.3.3 Problems of Immunity Engineering
- 5.3.4 The Role of Cost
- 5.3.5 The Disruption Dynamic
5.4 Global Sales of Antibody-drug Conjugates (ADCs) in 2024
- 5.4.1 Enhertu Sales in 2024/2023
- 5.4.2 Kadcyla Sales in 2024/2023
- 5.4.3 Padcev Sales in 2024/2023
- 5.4.4 Adcetris Sales in 2024/2023
- 5.4.5 Trodelvy Sales in 2024/2023
- 5.4.6 Polivy Sales in 2024/2023
- 5.4.7 The Next Five Years

6 ADC Recent Developments

6.1 Recent Developments - Importance and How to Use This Section
- 6.1.1 Importance of These Developments
- 6.1.2 How to Use This Section
6.2 Merck secures $700 million to develop ADC therapy
6.3 Enhertu tops Roche's Kadcyla
6.4 Innovent signs $11.4 billion cancer therapy deal with Takeda
6.5 Tubulis raises $358 million to develop targeted cancer treatments
6.6 Roche closes $80M deal for lung cancer ADC
6.7 Trodelvy and Keytruda combo succeeds in Phase 3
6.8 GSK acquires rights for prostate cancer ADC
6.9 Samsung Bioepis and Phrontline partner for ADC development
6.10 Phrontline Biopharma raises $60M for bispecific and dual-payload ADCs
6.11 Kelun has phase 3 win for ADC-Keytruda combo
6.12 Datopotamab deruxtecan Biologics License Application accepted
6.13 FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors
6.14 AstraZeneca to build $1.5-bln ADC plant
6.15 Samsung Biologics expands into ADC manufacturing and services
6.16 Ipsen and Foreseen Biotechnology announce licensing agreement for ADC
6.17 PDCs vs. ADCs: A New Frontier
6.18 MilliporeSigma launches single-use reactor for ADC manufacturing
6.19 Ono to generate novel ADC candidates
6.20 Gilead and Tubulis to develop ADC candidate for solid tumor

7 Profiles of Key ADC Companies

7.1 ADC Therapeutics
7.2 AbbVie
7.3 Abzena
7.4 Adcendo
7.5 Adcentrx Therapeutics
7.6 Adcytherix
7.7 Alentis Therapeutics
7.8 Alphamab Oncology
7.9 Alteogen
7.10 Ambrx
7.11 Amgen
7.12 Antengene
7.13 Astellas Pharma
7.14 Axcynsis Therapeutics
7.15 Axplora
7.16 BeiGene
7.17 BeOne Medicines
7.18 BioAtla
7.19 Bio-Thera Solutions
7.20 Biotheus
7.21 BiVictriX Therapeutics
7.22 BioNTech
7.23 Bicycle Therapeutics
7.24 Bolt Biotherapeutics
7.25 Bright Peak Therapeutics
7.26 Bristol Myers Squibb (BMS)
7.27 Byondis
7.28 Callio Therapeutics
7.29 Catalent Biologics
7.30 CSPC Pharmaceutical Group
7.31 CytomX Therapeutics
7.32 Daiichi Sankyo
7.33 Debiopharm
7.34 Duality Biologics
7.35 Eisai
7.36 Eli Lilly
7.37 Exelixis
7.38 Fosun Pharma
7.39 Genentech (Roche)
7.40 Genmab
7.41 GenScript Biotech
7.42 Gilead Sciences
7.43 GlaxoSmithKline (GSK)
7.44 Hansoh Pharma
7.45 Hengrui Pharma
7.46 Heidelberg Pharma
7.47 Iksuda Therapeutics
7.48 ImmunoGen
7.49 Innate Pharma
7.50 Innovent Biologics
7.51 iProgen Biotech
7.52 Janssen Biotech (Johnson & Johnson)
7.53 Kelun-Biotech
7.54 KLUS Pharma
7.55 LegoChem Biosciences (LegoChemBio)
7.56 Lepu Biopharma
7.57 Lonza Pharma & Biotech / Synaffix
7.58 MacroGenics
7.59 MBrace Therapeutics
7.60 MediLink Therapeutics
7.61 Merck & Co. (MSD)
7.62 Merck KGaA (EMD Serono)
7.63 Mersana Therapeutics
7.64 Molecular Templates
7.65 NBE Therapeutics (a subsidiary of Boehringer Ingelheim)
7.66 Novartis
7.67 OBI Pharma
7.68 OmniAb
7.69 Oncomatryx
7.70 OnCusp Therapeutics
7.71 Orum Therapeutics
7.72 Oqory
7.73 Oxford BioTherapeutics
7.74 Pacylex Pharmaceuticals
7.75 Pfizer
7.76 Phrontline Biopharma
7.77 ProfoundBio
7.78 Promega
7.79 Pyxis Oncology
7.80 Radiance Biopharma
7.81 Rakuten Aspyrian (Aspyrian Therapeutics)
7.82 RemeGen
7.83 Roche
7.84 Rongchang Pharmaceuticals (RCBio)
7.85 Sanofi
7.86 Seagen
7.87 Solve Therapeutics (Solve Tx)
7.88 Sorrento Therapeutics
7.89 Starpharma
7.90 Sutro Biopharma
7.91 Synaffix (a Lonza Company)
7.92 SystImmune
7.93 Takeda Pharmaceutical
7.94 Tesaro / GSK Oncology
7.95 Tubulis
7.96 UCB
7.97 VelosBio
7.98 WuXi XDC
7.99 Xencor
7.100 Zai Lab

8 The Global Market for ADC Therapeutics

8.1 Global Market Overview by Country
- 8.1.1 Table - Global Market by Country
- 8.1.2 Chart - Global Market by Country
8.2 Global Market by Cancer - Overview
- 8.2.1 Table - Global Market by Cancer
- 8.2.2 Chart - Global Market by Cancer - Base/Final Year
- 8.2.3 Chart - Global Market by Cancer - Base Year
- 8.2.4 Chart - Global Market by Cancer - End Year
- 8.2.5 Chart - Global Market by Cancer - Share by Year
- 8.2.6 Chart - Global Market by Cancer - Segments Growth
8.3 Global Market by Payload - Overview
- 8.3.1 Table - Global Market by Payload
- 8.3.2 Chart - Global Market by Payload - Base/Final Year
- 8.3.3 Chart - Global Market by Payload - Base Year
- 8.3.4 Chart - Global Market by Payload - End Year
- 8.3.5 Chart - Global Market by Payload - Share by Year
- 8.3.6 Chart - Global Market by Payload - Segments Growth
8.4 Global Market by Target - Overview
- 8.4.1 Table - Global Market by Target
- 8.4.2 Chart - Global Market by Target - Base/Final Year Comparison
- 8.4.3 Chart - Global Market by Target - Base Year
- 8.4.4 Chart - Global Market by Target - End Year
- 8.4.5 Chart - Global Market by Target - Share by Year
- 8.4.6 Chart - Global Market by Target - Segments Growth
8.5 Global Market by Product - Overview
- 8.5.1 Table - Global Market by Product
- 8.5.2 Chart - Global Market by Product - Base/Final Year Comparison
- 8.5.3 Chart - Global Market by Product - Base Year
- 8.5.4 Chart - Global Market by Product - End Year
- 8.5.5 Chart - Global Market by Product - Share by Year
- 8.5.6 Chart - Global Market by Product - Segments Growth
8.6 Global Market by User - Overview
- 8.6.1 Table - Global Market by User
- 8.6.2 Chart - Global Market by User - Base/Final Year Comparison
- 8.6.3 Chart - Global Market by User - Base Year
- 8.6.4 Chart - Global Market by User - End Year
- 8.6.5 Chart - Global Market by User - Share by Year
- 8.6.6 Chart - Global Market by User - Segments Growth

9 Global ADC Markets - By Cancer

9.1 Breast
- 9.1.1 Table Breast - by Country
- 9.1.2 Chart - Breast Growth
9.2 Blood/Lymph Cancer
- 9.2.1 Table Blood Cancer - by Country
- 9.2.2 Chart - Blood Cancer Growth
9.3 Lung Cancer
- 9.3.1 Table Lung Cancer - by Country
- 9.3.2 Chart - Lung Cancer Growth
9.4 Other Cancer
- 9.4.1 Table Other Cancer - by Country
- 9.4.2 Chart - Other Cancer Growth

10 ADC Therapeutic Markets - By Payload

10.1 Auristatin
- 10.1.1 Table Auristatin - by Country
- 10.1.2 Chart - Auristatin Growth
10.2 Maytansinoid
- 10.2.1 Table Maytansinoid - by Country
- 10.2.2 Chart - Maytansinoid Growth
10.3 Topoisomerase
- 10.3.1 Table Topoisomerase - by Country
- 10.3.2 Chart - Topoisomerase Growth
10.4 Other Payload
- 10.4.1 Table Other Payload - by Country
- 10.4.2 Chart - Other Payload Growth

11 ADC Therapeutic Markets - By Target

11.1 HER2
- 11.1.1 Table HER2 - by Country
- 11.1.2 Chart - HER2 Growth
11.2 CD30
- 11.2.1 Table CD30 - by Country
- 11.2.2 Chart - CD30 Growth
11.3 TROP2
- 11.3.1 Table TROP2 - by Country
- 11.3.2 Chart - TROP2 Growth
11.4 CD79b
- 11.4.1 Table CD79b - by Country
- 11.4.2 Chart - CD79b Growth
11.5 Nectin 4
- 11.5.1 Table Nectin 4 - by Country
- 11.5.2 Chart - Nectin 4 Growth
11.6 Other Target
- 11.6.1 Table Other Target - by Country
- 11.6.2 Chart - Other Target Growth

12 ADC Therapeutic Markets - By Product

12.1 Enhertu
- 12.1.1 Table Enhertu - by Country
- 12.1.2 Chart - Enhertu Growth
12.2 Kadcyla
- 12.2.1 Table Kadcyla - by Country
- 12.2.2 Chart - Kadcyla Growth
12.3 Padcev
- 12.3.1 Table Padcev - by Country
- 12.3.2 Chart - Padcev Growth
12.4 Adcetris
- 12.4.1 Table Adcetris - by Country
- 12.4.2 Chart - Adcetris Growth
12.5 Trodelvy
- 12.5.1 Table Trodelvy - by Country
- 12.5.2 Chart - Trodelvy Growth
12.6 Polivy
- 12.6.1 Table Polivy - by Country
- 12.6.2 Chart - Polivy Growth
12.7 Other Product
- 12.7.1 Table Other Product - by Country
- 12.7.2 Chart - Other Product Growth

13 ADC Therapeutic Markets - By User

13.1 Clinical
- 13.1.1 Table Clinical - by Country
- 13.1.2 Chart - Clinical Growth
13.2 Trial
- 13.2.1 Table Trial - by Country
- 13.2.2 Chart - Trial Growth
13.3 Research
- 13.3.1 Table Research - by Country
- 13.3.2 Chart - ResearchGrowth
13.4 Other User
- 13.4.1 Table Other User - by Country
- 13.4.2 Chart - Other User Growth